Brief: Matinas BioPharma Reports Q4 Loss Per Share Of $0.03
29/03/2021 12:22
March 29 (Reuters) - Matinas BioPharma Holdings Inc
MTNB.A :
* MATINAS BIOPHARMA REPORTS FOURTH QUARTER AND FULL YEAR
2020
FINANCIAL RESULTS AND OPERATIONAL HIGHLIGHTS
* Q4 LOSS PER SHARE $0.03
* Q4 EARNINGS PER SHARE ESTIMATE $-0.03 -- REFINITIV IBES
DATA
* MATINAS BIOPHARMA - ENROLLMENT CONTINUES IN SECOND PATIENT
COHORT OF ENACT STUDY OF MAT2203 IN CRYPTOCOCCAL MENINGITIS
* MATINAS BIOPHARMA - DSMB REVIEW AND COHORT PROGRESSION IN
ENACT
STUDY OF MAT2203 IN CRYPTOCOCCAL MENINGITIS IS ANTICIPATED IN Q3
OF 2021
* CASH ON HAND IS SUFFICIENT TO FUND OPERATIONS INTO 2024
Source text for Eikon: ID:nGNX5sQHSy
Further company coverage: MTNB.A
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Matinas BioPharma Holdings
See all newsBrief: GH Power Signs Multi-Year Hydrogen Offtake Agreement With Change Energy For Hamilton Facility Output
Brief: Gh Power And Tkms Continue To Explore Clean Energy Collaboration In Support Of Canada’S Future Patrol Submarine Project
Brief: Matinas Biopharma - Btig Terminates Sales Agreement With Matinas Biopharma Holdings, Effective Immediately On July 23, 2026 - SEC Filing
Brief: Matinas Biopharma Receives Notice Of Non-Compliance With NYSE American Continued Listing Standards And Acceptance Of Plan To Regain Compliance
Brief: Matinas Biopharma - May Offer Securities Up To $150 Million - SEC Filing